BPC-157 / thymosin alpha-1 stack: what's in it
- 2 sources
- How we source
- We don't sell peptides. We never link "research use only" sellers.
The short answer
BPC-157 / thymosin alpha-1 stack combines BPC-157 and Thymosin alpha-1.
The parts
Not FDA-approved · advisory vote July 2026 · no FDA decision
WADA 2026: S0
BPC-157 Papers on animals 103 Lab-dish (cell) papers 1 Papers PubMed tags as about people 55 Registered trials (ClinicalTrials.gov) 2 of 3 search results name BPC-157 Randomized trials in people none found Approved outside the US
Bars are counts of papers or trials; a longer bar means more studies, not better results. Study counts auto-counted from PubMed tags and ClinicalTrials.gov in the Ellum research database, as of October 6, 2026 (not reviewed; a paper can carry more than one tag). Papers PubMed tags as about people: includes reviews and case reports; not randomized trials. All bars share one scale. Each count is for that part alone.
Regulatory status by component
Not FDA-approved How we label status
- As of October 4, 2026, BPC-157 is not FDA-approved. On July 23, 2026, FDA's compounding advisory committee voted to recommend adding it to the 503A bulks list; FDA staff had recommended against it. FDA has not proposed that change. See BPC-157 in the Index →
- As of October 4, 2026, Thymosin alpha-1 is not FDA-approved for any use and is not on FDA's 503A bulks list. It is approved in Italy. See Thymosin alpha-1 in the Index →
Status as of October 4, 2026
- As a combination
- No category as a combination (see components)
Get updates on BPC-157 / thymosin alpha-1 stack
The research on BPC-157 / thymosin alpha-1 stack
Key facts
Also known as: bpc-157 thymosin alpha-1, bpc ta1
- Parts
- BPC-157 and Thymosin alpha-1
- Route
- injectable;oral
References
Status sources
Sources as of October 4, 2026
What this doesn’t establish
Results for one compound don't tell you what the two do together.